logo
NIH cuts have doomed my research in Bangladesh — but US citizens will pay too

NIH cuts have doomed my research in Bangladesh — but US citizens will pay too

Boston Globe29-05-2025

For more than 15 years, I have conducted studies in Bangladesh, a country that has extremely high levels of arsenic in its drinking water supply — meaning the population is routinely exposed to a lot of arsenic. My collaborators are pediatric neurologists like me, as well as neurosurgeons, medics, nurses, and community health workers, all professionals dedicated to understanding how arsenic affects the neurological development of children.
Get The Gavel
A weekly SCOTUS explainer newsletter by columnist Kimberly Atkins Stohr.
Enter Email
Sign Up
We have received generous support from US taxpayers through their investments in the NIH. When I submit a grant application, the NIH asks me to justify why taxpayer dollars are being spent outside the country. It is easy for me to provide this justification. Arsenic affects many areas of the United States, including here in New England. But the widespread high levels of arsenic in Bangladesh, and the much larger number of people exposed to it, make conducting studies there more efficient and less expensive. Our studies have led to changes in Bangladesh's health policy, including recommendations to establish dietary standards for folate, a vitamin that counters the toxic effects of arsenic. This work also has helped us develop solutions that are relevant to US families, such as setting regulations for acceptable levels of arsenic in public water systems.
Advertisement
There are many examples of research conducted abroad that benefit people in the United States. Oral rehydration therapy, the standard treatment for childhood diarrhea, was developed by scientists in India and Bangladesh who worked with US partners funded by the US government. Collaborations with researchers in Colombia led to the identification of a rare genetic variant associated with a delay in dementia onset; this finding provides potential targets for therapies for Alzheimer's disease.
Advertisement
NIH-funded studies in Africa led to the development of self-collection swabs for cervical cancer screening. And just this month, the Food and Drug Administration
Our recent experiences with COVID-19, Zika, and Ebola confirm that there are no borders to infectious diseases and that global scientific cooperation can lead to faster and more effective responses to them. To address climate change, an even greater health threat, research with foreign collaborators aids knowledge-sharing and innovation. Earlier this year, I participated in a simulation of a heat emergency in Arizona that was conducted by a research team who drew lessons from their work in western India — which taught them more about how extreme temperatures affect human physiology.
It hasn't always been necessary to invoke US health interests to justify scientific research abroad. In 2003, the global HIV/AIDS epidemic led to the President's Emergency Plan for AIDS relief (PEPFAR). Over the past 20 years, PEPFAR, together with NIH funding, has expanded what we know about HIV/AIDS and turned what was once a death sentence into a manageable condition for millions worldwide.
Advertisement
The NIH states that the motivation for its new policy is 'to improve the tracking of federal dollars and the security of the US biomedical research enterprise.' These are goals that no one can argue with. In 2023, the NIH began requiring foreign collaborators to provide copies to their US partners of all lab notebooks, all data, and all other documentation that is produced as part of research projects. In my own program, this has meant more frequent site visits to Bangladesh, a transition to electronic record-keeping, and more detailed monitoring of expenses and receipts. It must be possible to further strengthen these efforts to provide oversight without stopping the collaborations altogether.
I submitted an application to the NIH in November 2024, just days before the presidential election, that had the words 'global partnerships' in the title. It has not yet been reviewed. When I wrote those words, I believed they would be viewed as a strength of the proposal. That is no longer the case. But I am not deterred. Like many in my position, I am looking elsewhere — foundations, philanthropy, industry, other countries — for new sources of funding. If the United States will not lead the world in scientific research, I hope others will step up. So if you're a foundation or industry leader reading this and you're interested, I have a research grant proposal ready for you.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

This common kitchen herb ingredient could help target or slow Alzheimer's
This common kitchen herb ingredient could help target or slow Alzheimer's

New York Post

timean hour ago

  • New York Post

This common kitchen herb ingredient could help target or slow Alzheimer's

Experts believe they've identified a chemical compound in certain herbs that could help mitigate or prevent Alzheimer's disease — but before anyone makes a run for the spice rack, there are a few catches. In a study published in the journal Antioxidants earlier this year, researchers from the Scripps Research Institute identified a compound called carnosic acid, which is prevalent in rosemary and sage. Advertisement The compound could prove therapeutic for neurodegenerative disorders, including Alzheimer's disease, the experts concluded. Carnosic acid contains 'striking antioxidant [and] anti-inflammatory properties,' the researchers wrote in the findings. Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, based in California, spoke with Fox News Digital about the results. 'In this study, we observed that administering this drug to mice that had advanced Alzheimer's-like disease significantly improved the number of neurons, as well as the number of synapses or connections between the brain cells,' the team said. Advertisement 4 Experts believe they've identified a chemical compound, carnosic acid, in certain herbs like rosemary and sage that could help mitigate or prevent Alzheimer's disease. Brent Hofacker – The experts added, 'It also reduced inflammation that is caused by the current anti-amyloid antibody therapies. We also observed an improvement in the learning and memory behavior of the mice that received the drug.' Banerjee and Lipton also noted that carnosic acid is a 'prodrug,' meaning it's inactive at first — but once it enters the body, it's activated by oxidative and inflammatory stress. 'It specifically targets cells undergoing oxidative and inflammatory stress, without affecting the healthy, normal brain cells,' Banerjee said. Advertisement 'This further makes it a safe option for therapeutics.' The experts agreed that carnosic acid could potentially improve the inflammation that generally occurs in most aging brains. There are cautions, however. Advertisement Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, told Fox News Digital that studies based on a mouse model of Alzheimer's can be helpful but are not conclusive. 4 Experts say carnosic acid could improve inflammation occurring in most aging brains. LIGHTFIELD STUDIOS – 'Models are important in helping us understand the basic biology of the disease, but we need human studies in representative populations for ideas to be fully validated,' Kloske said. 'Therefore, while these are intriguing findings, more research is needed to understand the impacts and outcomes of these compounds on people living with, or at risk for, Alzheimer's.' Cooking sage and rosemary won't provide the full anti-inflammatory effects, Banerjee and Lipton stressed. 4 'We need human studies in representative populations for ideas to be fully validated,' Courtney Kloske, director of scientific engagement for the Chicago-based Alzheimer's Association, says about the limitations of the information. – 'Critically, one cannot take sufficient herbs safely to produce the same effect as our new drug,' Banerjee said. The study, funded in part by the National Institutes of Health, did have some limitations, the researchers acknowledged. Advertisement Kloske advised that, at this point, 'no one should consume these herbs (or carnosic acid) to prevent or treat Alzheimer's or other cognitive impairment.' 4 According to Scripps Research postdoctoral associate Piu Banerjee and board-certified neurologist Dr. Stuart Lipton, cooking sage and rosemary won't provide the full anti-inflammatory effects. Ganna – Dr. Lee Murray, a neurologist in Jackson, Tennessee, echoed Kloske's concerns. 'Before patients start incorporating rosemary and sage in every dish they eat, we need to remember these studies are pre-clinical,' Murray told Fox News Digital. Advertisement 'Currently, there is insufficient clinical evidence to recommend rosemary and sage as a standard therapy for Alzheimer's dementia.' Murray, however, said the data 'is encouraging' and opens the door to additional pathways for potential therapeutics. Banerjee said she hopes that 'our drug will start human clinical trials soon.' She added, 'If it proves to be effective, it will be a great new drug for those suffering from Alzheimer's … From the results of our animal studies, we are cautiously optimistic for its success in human clinical trials.'

New Study Finds That A Blood Test For Diabetes Might Actually Predict Alzheimer's Progression
New Study Finds That A Blood Test For Diabetes Might Actually Predict Alzheimer's Progression

Yahoo

time6 hours ago

  • Yahoo

New Study Finds That A Blood Test For Diabetes Might Actually Predict Alzheimer's Progression

A new study suggests a simple blood test could tell who is at higher risk for rapid cognitive decline with Alzheimer's. The study found that people with higher insulin resistance were up to four times more likely to have rapid cognitive decline. Here's what to know about the test and how to get one. Historically, it has been quite difficult for doctors to predict how fast patients will experience cognitive decline with Alzheimer's disease, especially since the neurodegenerative disease impacts people differently based on a slew of factors. But new research has discovered that a specific blood test may help doctors get more answers, which could, in theory, help them respond more quickly with appropriate treatment and providing patients with more information. (But of course, experts first need to gather more data and perform further studies on the test.) The test measures insulin resistance, a condition where the body's cells don't respond properly to insulin, a hormone that helps escort blood sugar into cells for energy. The latest study finds a link between insulin resistance and Alzheimer's disease progression, helping doctors and patients glean more information about what may be in store. Here's what the study found, plus what neurologists want you to know. Meet the experts: Clifford Segil, DO, is a neurologist at Providence Saint John's Health Center in Santa Monica, CA; Amit Sachdev, MD, MS, is the medical director in the Department of Neurology at Michigan State University. The study, which was presented at the European Academy of Neurology Congress 2025, analyzed health records of 315 people without diabetes who had cognitive deficits. Of those, 200 had confirmed cases of Alzheimer's disease. All of the patients had their insulin resistance checked using something called the Triglyceride-Glucose (TyG) index, a way to check insulin resistance, based on fasting triglyceride (a type of fat in the blood) and blood sugar levels, at the start of the study and three years later. The researchers discovered that patients in the mild cognitive impairment group with higher TyG levels had their cognitive health deteriorate a lot faster than those who were lower on the TyG index. Ultimately, the researchers found that people with higher TyG levels were up to four times more likely to have rapid cognitive decline compared to those who were lower on the scale. For starters, this type of blood test isn't actually new. We're just discovering new ways it can be used. The TyG index is already used to look for insulin resistance in people, so technically, you could get this test now if your doctor thought that it was medically appropriate. Just know that it's usually used in the context of diabetes or when your doctor suspects you might have diabetes. The test appears to be pretty accurate in predicting rapid mental decline. The researchers found that people with high TyG ended up losing more than 2.5 points on the Mini Mental State Examination per year, which is a standardized test used to look at cognitive function in older adults. In Alzheimer's disease, insulin resistance is thought to interfere with how the brain uses glucose (blood sugar). It's also believed to promote the build-up of amyloid, or proteins deposits in the brain that are linked with Alzheimer's disease. Additionally, insulin resistance can disrupt the blood-brain barrier and fuel inflammation in the brain. All of these are linked with neurodegenerative diseases like Alzheimer's disease. 'Insulin resistance often reflects features of overall health," says Amit Sachdev, MD, MS, medical director in the Department of Neurology at Michigan State University, pointing out that a major contributor to insulin resistance is higher bodyweight. 'If the overall health of the body is not optimal, then the brain will not be well supported and can be less resilient.' But the link between insulin resistance and Alzheimer's disease is still being explored, says Clifford Segil, DO, a neurologist at Providence Saint John's Health Center in Santa Monica, CA. So, while it's clear that it seems to play some role, it's hard to tell what it's specifically doing as it relates to brain health. Your doctor can order one of these tests for you. However, neurologists say there are better options right now if you're concerned about Alzheimer's disease development and are looking for answers. 'Some tests that are more specific for Alzheimer's are serum amyloid and tau levels,' Dr. Sachdev sys. 'Tests that help predict risk for the anti-amyloid therapies used in Alzheimer's is the APO-E genotype. These studies are useful today in understand risk of dementia, type of dementia, and risk of treatment.' Dr. Segil says that doctors are 'extremely cautious' about using blood tests like TyG to determine if someone is at risk for developing dementia in the first place. 'There remains an extremely high number of false positive results in patients receiving various blood tests being marketed to determine if you are at risk for getting dementia,' he says. However, this specific study is exploring the test to see how quickly someone who already has cognitive decline will progress—and that usage is still being explored. All of this doesn't mean you can't or shouldn't get a TyG test. Just know that your doctor is more likely to use it while checking you for early signs of diabetes versus Alzheimer's disease right now. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Yahoo

time9 hours ago

  • Yahoo

Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer

Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds. On June 25, Gilead Sciences expanded its oncology pipeline through an exclusive agreement with Kymera Therapeutics Inc. (NASDAQ:KYMR). This deal is potentially valued at up to $750 million and focuses on advancing Kymera's innovative molecular glue degrader/MGD program targeting cyclin-dependent kinase 2/CDK2. Gilead will make an upfront payment of up to $85 million, with additional payments contingent on future development milestones and product sales, plus tiered royalties on net product sales. Kymera's MGDs are designed to selectively eliminate CDK2, which is a protein crucial for cell division that often drives uncontrolled growth in various cancers, such as breast cancer and other solid tumors. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. Unlike traditional CDK2 inhibitors that merely block protein activity, MGDs aim to remove the protein entirely. Kymera will lead all research activities for the CDK2 program. If Gilead exercises its option, it will gain worldwide rights to develop, manufacture, and commercialize all resulting products. This move for Gilead follows closely on the heels of the US FDA approval of Yeztugo (lenacapavir) for HIV prevention. Gilead Sciences Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in the areas of unmet medical needs. Kymera Therapeutics Inc. (NASDAQ:KYMR) is a clinical-stage biopharmaceutical company that discovers and develops small-molecule therapeutics. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store